Echelon Ventures
VC Fund
Waltham, United States
Echelon Ventures is a venture capital firm specialized in early stage investments.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Echelon Ventures invests in
Stages Echelon Ventures invests in
Countries Echelon Ventures invests in
Investment Focus
Industry
- Genetics 1 (33%)
- Health Care 1 (33%)
- Open Source 1 (33%)
- Life Science 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series B 1 (33%)
- Funding Round 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Avedro
|
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the UnitedStates, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States. | $8M / Series A / Jan 31, 2008 | |
BioTrove
|
BioTrove, Inc. provides micro and nano-scale technology platforms for life science and drug discovery research applications. The company offers OpenArray, a technology platform for relative gene expression analysis that advances genomic research in various life science fields, including agriculture, disease research, and public health; RapidFire, atechnology platform that enables the screening of intractable drug targets via mass spectrometry based assay development; and RapidFire mass spectrometry hardware system, a native detection technology for drug screening and in vitro ADME applications. | $7M / Mar 08, 2006 | |
Sitescape
|
Sitescape started out making open-source Web workspace and then it bought a conferencing solution and now it is addressing social networking. Sitescape clients include the US Navy, US Centers for Disease Control, the European Space Agency, Lockheed Martin, Shell, and Starwood Hotels. | $5M / Series B / Apr 22, 2002 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Echelon Ventures invest in?
Echelon Ventures invests primarily in Genetics, Health Care and Open Source startups, most often at Series B and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Echelon Ventures last invest?
The most recent investment recorded for Echelon Ventures closed in Jan 2008. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
